Association between Serum Cytokine Profiles and Schistosomiasis-Related Hepatic Fibrosis: Infection by Schistosoma japonicum versus S. mansoni

To the Editor—In the 1 August 2005 issue of the *Journal*, Coutinho et al. described, in patients infected by *Schistosoma japonicum*, a correlation between the levels of certain cytokines and the presence of hepatic fibrosis (HF) [1]; they found that the levels of both interleukin (IL–1) and IL–6 were higher in patients with HF than in patients without HF, and they also reported that the presence of HF was negatively correlated with body-mass index. We found these results to be particularly interesting, because we have noted a similar correlation between HF and immunological parameters.

We recently reported a relationship between anti–soluble egg antigen (anti–SEA)–isotype antibody responses and portal hypertension (PH) in *Schistosoma mansoni*–infected patients in Saint Louis, Senegal [2]. This hyperendemic situation is noteworthy in that the illness emerged after a recent change in the ecosystem—a dam was constructed on the Senegal River in 1986, and the first cases of schistosomiasis were diagnosed in 1988. The disease was severe and rapidly progressive, with the first cases of PH being observed in 1994 [3]. Using hepatic sonography and gastric fibroscopy, we have screened for HF in a cohort of 142 *S. mansoni*–infected patients; patients with HF were classified as belonging to 1 of 3 categories based on 3 stages of pathology: (1) those who were free of HF (no morbidity—i.e., clinical and hepatic ultrasound findings were normal); (2) those in whom hepatic ultrasound findings were abnormal but in whom gastric fibroscopy showed no signs of PH (moderate morbidity); and (3) those in whom gastric fibroscopy showed esophageal varices (severe morbidity). We found that the presence of PH—and, therefore, of HF—correlated positively with levels of anti–SEA IgG4, IgA, and IgE [2]. We also measured serum levels of pro- and anti-inflammatory factors—soluble intercellular cell-adhesion molecule-1, soluble tumor necrosis factor receptor-1 and –2, interferon (IFN)–γ, tumor necrosis factor (TNF)–α, and IL–10—in the same samples. High levels of an anti-inflammatory cytokine, such as IL–10, during the advanced stage of the disease may be linked to PH itself. Indeed, inflammation triggered by PH could lead to the secretion of anti-inflammatory cytokines, and these elevated levels of IL–10 would therefore reflect an attempt to dampen the inflammatory reaction. Other studies have also suggested a link between high levels of IL–10 and the severity of parasitic infections; for example, Perkins et al. [4] and Ho et al. [5] have reported that severe malaria is associated with elevated levels of IL–10.

Our findings show that the inflammatory balance is altered in *S. mansoni*–infected patients who have advanced HF. The differences between stages 2 (moderate HF) and 3 (severe HF) of the disease

Table 1. Levels of pro- and anti-inflammatory factors, for different stages of pathology of hepatic fibrosis.

<table>
<thead>
<tr>
<th>Cytokine</th>
<th>Stage 1 (n = 28)</th>
<th>Stage 2 (n = 10)</th>
<th>Stage 3 (n = 10)</th>
<th>P&lt;sup&gt;a&lt;/sup&gt; (stage 1 vs. stage 2)</th>
<th>P&lt;sup&gt;a&lt;/sup&gt; (stage 2 vs. stage 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>sTNFR-1, pg/mL</td>
<td>683 (531–1550)</td>
<td>.264</td>
<td>.241</td>
<td>744 (532–2128)</td>
<td></td>
</tr>
<tr>
<td>sTNFR-2, pg/mL</td>
<td>2264 (1403–6781)</td>
<td>.208</td>
<td>.031</td>
<td>1945 (1214–2953)</td>
<td></td>
</tr>
<tr>
<td>TNF–α, pg/mL</td>
<td>238 (0–921)</td>
<td>.113</td>
<td>.264</td>
<td>177 (22–2452)</td>
<td></td>
</tr>
<tr>
<td>sICAM-1, ng/mL</td>
<td>826 (62–2426)</td>
<td>.281</td>
<td>.157</td>
<td>604 (356–1142)</td>
<td></td>
</tr>
<tr>
<td>IL–10, pg/mL</td>
<td>141 (0–2914)</td>
<td>.339</td>
<td>.017</td>
<td>359 (79–3162)</td>
<td></td>
</tr>
<tr>
<td>IFN–γ, IU/mL</td>
<td>2.15 (0–6.2)</td>
<td>.022</td>
<td>.026</td>
<td>2 (0–10)</td>
<td></td>
</tr>
</tbody>
</table>

NOTE. Data are median (range) of values, unless otherwise indicated. IFN, interferon; IL, interleukin; sICAM, soluble intercellular cell-adhesion molecule; sTNFR, soluble tumor necrosis factor receptor; TNF, tumor necrosis factor.

*P< .05 (nonparametric Mann-Whitney test) was considered to be statistically significant; these values are in boldface type. A statistically significant difference (*P* = .031) also was found between stages 1 and 3, for both IL–10 and sICAM–1.
could serve as a means by which to monitor disease progression, without the need for invasive examinations (e.g., gastric fibroscopy to detect esophageal varices). Early detection of a change from a pro- to an anti-inflammatory cytokine profile could serve as a way to identify a high-risk population of patients who require closer clinical and biological monitoring. In the same way that antibody responses vary between stages 2 and 3 of the disease [1], the inflammatory profile changes as the disease progresses, suggesting that advanced stage of the disease are accompanied by an accelerated immune reaction. The concomitant increase in levels of IFN-γ during the later stage of the disease (i.e., stage 3 vs. stage 2) (table 1) implies the presence of a mechanism of this type.

Finally, the fact that, despite the difference in the parasite species studied (S. japonicum vs. S. mansoni), our results are similar to those of Coutinho et al. suggests that there is a common pathophysiological mechanism governing the onset and regulation of HF in patients with schistosomiasis.

Philippe Bonnard,1 Franck Remoué,2 Anne-Marie Schacht,2 Gilles Pialoux1, and Gilles Riveau1
1Service des Maladies Infectieuses et Tropicales, Université Pierre et Marie Curie, Hôpital Tenon (AP-HF), Paris, and 2Institut National de la Santé et de la Recherche Médicale, Unité 547, Institut Pasteur, Lille, France; 3Institut de Recherche et de Développement, UR24, Épidémiologie et Prévention, Dakar, Sénégal

References
4. Perkins DJ, Weinberg JB, Kremser PG. Reduced interleukin-12 and transforming growth factor–β1 in severe childhood malaria: rela-


Potential conflicts of interest: none reported.

Reprints or correspondence: Dr. Philippe Bonnard, Service des Maladies Infectieuses et Tropicales, Hôpital Tenon, 4 rue de la Chine, 75020 Paris, France (philippe.bonnard@tnn.aphp.fr).

The Journal of Infectious Diseases 2006;193:748–9 © 2006 by the Infectious Diseases Society of America. All rights reserved. 0022-1899/2006/19305-0018$15.00

Reply to Bonnard et al.

To the Editor—It is indeed interesting that, in their study in Senegal, Bonnard et al. [1] found elevated serum levels of interleukin (IL)–10 in patients with severe morbidity due to chronic Schistosoma mansoni infection—and that this finding was independent of age, sex, or S. mansoni egg count. These results are similar to the findings that my colleagues and I had reported in our article in the Journal [2], despite the following differences in the 2 studies’ populations and designs: (1) in the study by Bonnard et al., participants were recruited at a local health center, whereas our study was community based; (2) the age range in the study by Bonnard et al. was 11–80 years, versus 7–30 years in our study; (3) current schistosomiasis infection was not a requirement for participation in the study by Bonnard et al. if pathology as detected by ultrasonography or endoscopy was present, whereas in our study it was a requirement for all participants; and (4) the 2 studies used different systems for classification of hepatic fibrosis (HF).

It seems plausible that the immunoregulatory mechanism involved in the development of HF is similar across species. The idea of using noninvasive, immunologic screening tools to facilitate the detection of severe HF and/or associated morbidity is interesting. However, a few issues should be discussed in this regard. First, there is no evidence for a “change from a pro- to an anti-inflammatory cytokine profile” during the development of severe HF. On the contrary, as mentioned by Bonnard et al., as well as in the Discussion section of our article [2], the increased levels of serum IL-10 that are associated with severe HF likely reflect an attempt to dampen increased levels of proinflammatory cytokines. In line with this hypothesis, we found that both the level of IL-1 and the percentage of individuals with detectable levels of IL-6 were increased in subjects with severe HF [2]. Other studies have found increased levels of a proinflammatory cytokine, tumor necrosis factor (TNF)–α, and its receptor, soluble TNF receptor (sTNFR)–1, in individuals with severe hepatic morbidity [2–5]. In contrast, Bonnard et al. found decreased levels of sTNFR-2 in subjects with severe morbidity—and, with progression of morbidity, a decrease, followed by an increase, in levels of interferon (IFN)–γ.

Second, the determination of which cutoff values for levels of IL-10 should be used to discriminate between different stages of hepatic morbidity may be difficult. Even if studies with large numbers of individuals were used to determine these cutoff values, coinfection with other pathogens could interfere with their reliability. Serum IL-10 is likely not specific enough to qualify as a marker for schistosomiasis-associated hepatocellular fibrosis. Levels of cytokines produced in response to specific schistosome antigens could be used instead, to overcome the confounding effects of coinfection with other pathogens; however, such an assay is likely to be too expensive to have public-health utility in the developing world. Another issue concerns the possible influence of genetic polymorphisms in relation to cytokine responses. Polymorphisms in the IFN-γ receptor gene have been found that may be responsible for the susceptibility of certain individuals to severe HF [6]. Several IL-10 receptor gene polymorphisms may also be of biological significance [7], but their role in the de-
Development of schistosomiasis-associated HF is currently unknown. These polymorphisms could predispose to development of HF, which would further limit the suitability of serum IL-10 as a marker for hepatic morbidity.

Finally, Bonnard et al. have described other immunologic markers that are specific for schistosomiasis [8] and may be more suitable as markers for disease progression.

Hannah M. Coutinho
Center for International Health Research, Brown University, Providence, Rhode Island

References


Potential conflicts of interest: none reported.

Reprints or correspondence: Hannah M. Coutinho, Postdoctoral Research Associate, Center for International Health Research (CIHR), Rhode Island Hospital, Brown University Medical School, 125 Claverick St., Providence, RI 02903 (hannah_coutinho@brown.edu).

The Journal of Infectious Diseases 2006;193:749–50 © 2006 by the Infectious Diseases Society of America. All rights reserved. 0022-1899/2006/19305-0019$15.00